SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. will announce financial results for the fourth quarter and year ended 2007 after the markets close on Monday, February 11, 2007 and will hold a webcast teleconference at 4:30 p.m. EDT that day. Members of Anesiva’s management team will discuss financial results from the fourth quarter and full year 2007 as well as provide an overview of the company’s product pipeline, recent events and milestones.
Interested parties can listen to the live audio webcast by dialing (800) 340-6289 (international dial: (706) 634-1538) or by logging on to http://www.anesiva.com and going to the Investor Information page. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by dialing (800) 642-1687 (international dial: 706-645-9291) and giving the following pass code: 31729950. The webcast will be available until the company’s next quarterly financial results conference call.
Anesiva further announced that company management will present at the following events in February 2008:
-- BIO CEO & Investor Conference
Feb. 13, 2008 1:15 p.m. Eastern Time
Presentation:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ANSV&item_id=1752218
http://www.rothcp.com/main/Page.aspx?PageID=7010
Live audio webcasts of the presentations will also be available online via the Investor Relations portion of Anesiva’s website at http://www.anesiva.com. Please connect to Anesiva’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva’s pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva’s leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.
CONTACT: Carol DeGuzman, Senior Director, Investor Relations of Anesiva,
Inc., +1-650-246-6898, investors@anesiva.com; or Media, Carolyn Wang of
WeissComm Partners, +1-415-946-1065, cbwang@wcpglobal.com, for Anesiva,
Inc.
Web site: http://www.anesiva.com/
